CorMedix Inc. 8-K

What Happened

• CorMedix Inc. (CRMD) filed an 8-K (Regulation FD disclosure) on June 8, 2026, announcing that the U.S. Court of Appeals for the Federal Circuit in Melinta Therapeutics, LLC, et al. v. Nexus Pharmaceuticals, Inc. affirmed a district court judgment. The appeals court ruled that Nexus’s generic minocycline product infringed two of CorMedix’s patents and rejected Nexus’s invalidity challenge. The company furnished a press release as Exhibit 99.1.

Key Details

• Date of disclosure: June 8, 2026 (press release furnished as Exhibit 99.1).
• Court: United States Court of Appeals for the Federal Circuit.
• Case: Melinta Therapeutics, LLC, et al. v. Nexus Pharmaceuticals, Inc.
• Ruling: Affirmed district court judgment that Nexus’s generic minocycline infringed two CorMedix patents; Nexus’s invalidity challenge was rejected.

Why It Matters

• A Federal Circuit ruling affirming infringement and rejecting invalidity strengthens CorMedix’s legal position around its minocycline-related patents. That legal outcome may affect Nexus’s ability to market a competing generic product and is material information for investors assessing the company’s patent protection and competitive landscape. The 8-K provided the company’s disclosure of this court decision but did not include financial guidance or quantified financial impacts.